| Background: Research has shown endothelial cell injury plays an important role in atherosclerosis and development, However, such little research on endothelial cell injury in the regeneration and repair at present. Endothelial progenitor cells (EPCs) are precursor cell of endothelial cells, and involved in the vascular endothelial cells repair process. It is reported that the reduction of EPCs had related to cardiovascular disease risk factors. The dynamic changes and conventional therapy on the impact of EPCs yet to be worked out in patients with coronary heart disease, particularly in acute myocardial infarction patients.Objective: The study was intended to detect the changes of circulating EPCs and relations with the degree of coronary artery disease in patients with coronary heart disease (CHD), and compared with the number and function of endothelial progenitor cells in different doses of atorvastatin. We explored the change of endothelial progenitor cells in patients with coronary heart disease and effects of statins medicine on progenitor cells, in order to lay the foundations for a new treatment of coronary heart disease.Methods: Eighty three for patients with CHD were enrolled in this study from May to November 2006. They divided into acute myocardial infarction interventional treatment group (group A, n=25), acute myocardial infarction conservative treatment group (group B, n=19), angina group (group C,n=21), and stable angina group (group D, n=18). Meanwhile10 patients with coronary angiography negative were selected as control group(group E,n=10).All the patients were bleed in immediately (Acute myocardial infarction average time of 2.5±1.5 hours) , 24 hours, 48 hours, 72 hours, seven days, 14 days and one month . EPC as a marker CD133, andflow cytometry was used to detect cell marker CD133 patients. Respectively, 10 mg atorvastatin (trade name: LIPITOR) and 40 mg atorvastatin were cure in hospitalized patients with coronary artery disease as randomized double-blind principle. We observed them for one month.Results:1. EPCs (CD133) were both expressed in peripheral blood of patients with coronary heart disease and the control group. The level of CD133 in patients with group A and group B was less than group C, and group C was less than group D, group E was the most. Compared group A with group B, the time of the percentage of CD133 had no significant difference (P> 0.05); Compared the other group to group A and group B , the time of CD133 percentage point had significant difference (P <0.05).2. Acute myocardial infarction in patients with peripheral blood progenitor cells existed in the dynamic changes in a week, which interventional treatment group increased significantly 72 hours, and conservative treatment group was significantly higher in seven days. But there are no such changes in angina patients and non-patients with coronary heart disease.3. The level of endothelial progenitor cells in peripheral blood was negatively correlated with the degree of coronary artery disease. (r=-0.619,P<0.05)。4. Atorvastatin might increase the number of EPCs (CD133), however, no significant correlation with the dose.Conclusion: 1. The more severe in vascular disease, the less the number of EPCs in patients with coronary heart disease. The level of CD133 in patients with acute myocardial infarction was less than unstable angina patients, the stable angina patients was the most. 2. EPCs number of patients with acute myocardial infarction changed in a week. 3. Plus statins drugs might increase the number of EPCs, however, no significant correlation with the dose. .
|
PDF Full Text Request